Name: UMIN ID:
Unique ID issued by UMIN | UMIN000009827 |
---|---|
Receipt number | R000011511 |
Scientific Title | Botulinum toxin treatment for orofacial pain, bruxism or occlusal dysesthesia: (phase 2 patient study) Effect for the patients |
Date of disclosure of the study information | 2013/04/01 |
Last modified on | 2019/07/29 06:56:29 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/01/21 12:44:14 | ||
2 | Update | 2013/01/21 12:47:28 | Institutions |
|
3 | Update | 2014/07/25 18:20:12 | TEL Address TEL |
|
4 | Update | 2014/08/21 09:48:46 | Organization Organization Category of Funding Organization Nationality of Funding Organization Nationality of Funding Organization |
|
5 | Update | 2014/08/21 09:49:22 | Recruitment status |
|
6 | Update | 2016/07/25 06:33:51 | Basic design Randomization Randomization unit Blinding Control Blocking Concealment No. of arms Interventions/Control_1 Interventions/Control_1 Interventions/Control_2 Interventions/Control_2 Target sample size |
|
7 | Update | 2016/07/25 06:34:43 | Primary outcomes Primary outcomes |
|
8 | Update | 2017/01/25 07:02:35 | Name of primary person or sponsor Organization Category of Funding Organization |
|
9 | Update | 2017/07/26 12:20:49 | Interventions/Control_1 |
|
10 | Update | 2017/07/26 12:21:57 | Organization Division name Division name |
|
11 | Update | 2018/01/19 13:46:59 | Target sample size |
|
12 | Update | 2019/01/27 07:15:13 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
13 | Update | 2019/07/28 17:00:03 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of primary person or sponsor Organization Organization Address Address Tel |
|
14 | Update | 2019/07/29 06:55:36 | Recruitment status Date of IRB |
|
15 | Update | 2019/07/29 06:56:29 | Number of participants that the trial has enrolled |